Drug Profile
Research programme: cancer and cardiovascular disease cell therapy - Cryo-Cell International/EndGenitor Technologies
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cryo-Cell International; EndGenitor Technologies
- Class Cell therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 21 Aug 2008 Early research in Cancer in USA (unspecified route)